Pravastatin and cognitive function in the elderly. Results of the PROSPER study

S. Trompet; P. van Vliet; A.J. de Craen; J. Jolles; B.M. Buckley; E.H. Gronenschild; M.B. Murphy; I. Ford; P.W. Macfarlane; N. Sattar; C.J. Packard; D.J. Stott; J. Shepherd; E.L. Bollen; G.J. Blauw; J.W. Jukema; R.G. Westendorp

doi:10.1007/s00415-009-5271-7

Pravastatin and cognitive function in the elderly. Results of the PROSPER study

S. Trompet, P. van Vliet, A.J. de Craen, J. Jolles, B.M. Buckley, E.H. Gronenschild, M.B. Murphy, I. Ford, P.W. Macfarlane, N. Sattar, C.J. Packard, D.J. Stott, J. Shepherd, E.L. Bollen, G.J. Blauw, J.W. Jukema, R.G. Westendorp

Clinical Child and Family Studies

Research output: Contribution to Journal › Article › Academic › peer-review

219 Downloads (Pure)

Abstract

Observational studies have given conflicting results about the effect of statins in preventing dementia and cognitive decline. Moreover, observational studies are subject to prescription bias, making it hard to draw definite conclusions from them. Randomized controlled trials are therefore the preferred study design to investigate the association between statins and cognition. Here we present detailed cognitive outcomes from the randomized placebo-controlled PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Cognitive function was assessed repeatedly in all 5,804 PROSPER participants at six different time points during the study using four neuropsychological performance tests. After a mean follow-up period of 42 months, no difference in cognitive decline at any of the cognitive domains was found in subjects treated with pravastatin compared to placebo (all p > 0.05). Pravastatin treatment in old age did not affect cognitive decline during a 3 year follow-up period. Employing statin therapy in the elderly in an attempt to prevent cognitive decline therefore seems to be futile. © 2009 Springer-Verlag.

Original language	English
Pages (from-to)	85-90
Number of pages	6
Journal	Journal of Neurology
Volume	257
Issue number	1
DOIs	https://doi.org/10.1007/s00415-009-5271-7
Publication status	Published - 2009

Access to Document

10.1007/s00415-009-5271-7

259174Final published version, 182 KB

Fingerprint Dive into the research topics of 'Pravastatin and cognitive function in the elderly. Results of the PROSPER study'. Together they form a unique fingerprint.

Cite this

Trompet, S., van Vliet, P., de Craen, A. J., Jolles, J., Buckley, B. M., Gronenschild, E. H., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., Stott, D. J., Shepherd, J., Bollen, E. L., Blauw, G. J., Jukema, J. W., & Westendorp, R. G. (2009). Pravastatin and cognitive function in the elderly. Results of the PROSPER study. Journal of Neurology, 257(1), 85-90. https://doi.org/10.1007/s00415-009-5271-7

Trompet, S. ; van Vliet, P. ; de Craen, A.J. ; Jolles, J. ; Buckley, B.M. ; Gronenschild, E.H. ; Murphy, M.B. ; Ford, I. ; Macfarlane, P.W. ; Sattar, N. ; Packard, C.J. ; Stott, D.J. ; Shepherd, J. ; Bollen, E.L. ; Blauw, G.J. ; Jukema, J.W. ; Westendorp, R.G. / Pravastatin and cognitive function in the elderly. Results of the PROSPER study. In: Journal of Neurology. 2009 ; Vol. 257, No. 1. pp. 85-90.

@article{b96dbb973ba345c0bac49fe7f2a9fa71,

title = "Pravastatin and cognitive function in the elderly. Results of the PROSPER study",

abstract = "Observational studies have given conflicting results about the effect of statins in preventing dementia and cognitive decline. Moreover, observational studies are subject to prescription bias, making it hard to draw definite conclusions from them. Randomized controlled trials are therefore the preferred study design to investigate the association between statins and cognition. Here we present detailed cognitive outcomes from the randomized placebo-controlled PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Cognitive function was assessed repeatedly in all 5,804 PROSPER participants at six different time points during the study using four neuropsychological performance tests. After a mean follow-up period of 42 months, no difference in cognitive decline at any of the cognitive domains was found in subjects treated with pravastatin compared to placebo (all p > 0.05). Pravastatin treatment in old age did not affect cognitive decline during a 3 year follow-up period. Employing statin therapy in the elderly in an attempt to prevent cognitive decline therefore seems to be futile. {\textcopyright} 2009 Springer-Verlag.",

author = "S. Trompet and {van Vliet}, P. and {de Craen}, A.J. and J. Jolles and B.M. Buckley and E.H. Gronenschild and M.B. Murphy and I. Ford and P.W. Macfarlane and N. Sattar and C.J. Packard and D.J. Stott and J. Shepherd and E.L. Bollen and G.J. Blauw and J.W. Jukema and R.G. Westendorp",

year = "2009",

doi = "10.1007/s00415-009-5271-7",

language = "English",

volume = "257",

pages = "85--90",

journal = "Journal of Neurology",

issn = "0340-5354",

publisher = "D. Steinkopff-Verlag",

number = "1",

}

Trompet, S, van Vliet, P, de Craen, AJ, Jolles, J, Buckley, BM, Gronenschild, EH, Murphy, MB, Ford, I, Macfarlane, PW, Sattar, N, Packard, CJ, Stott, DJ, Shepherd, J, Bollen, EL, Blauw, GJ, Jukema, JW & Westendorp, RG 2009, 'Pravastatin and cognitive function in the elderly. Results of the PROSPER study', Journal of Neurology, vol. 257, no. 1, pp. 85-90. https://doi.org/10.1007/s00415-009-5271-7

Pravastatin and cognitive function in the elderly. Results of the PROSPER study. / Trompet, S.; van Vliet, P.; de Craen, A.J.; Jolles, J.; Buckley, B.M.; Gronenschild, E.H.; Murphy, M.B.; Ford, I.; Macfarlane, P.W.; Sattar, N.; Packard, C.J.; Stott, D.J.; Shepherd, J.; Bollen, E.L.; Blauw, G.J.; Jukema, J.W.; Westendorp, R.G.

In: Journal of Neurology, Vol. 257, No. 1, 2009, p. 85-90.

Research output: Contribution to Journal › Article › Academic › peer-review

TY - JOUR

T1 - Pravastatin and cognitive function in the elderly. Results of the PROSPER study

AU - Trompet, S.

AU - van Vliet, P.

AU - de Craen, A.J.

AU - Jolles, J.

AU - Buckley, B.M.

AU - Gronenschild, E.H.

AU - Murphy, M.B.

AU - Ford, I.

AU - Macfarlane, P.W.

AU - Sattar, N.

AU - Packard, C.J.

AU - Stott, D.J.

AU - Shepherd, J.

AU - Bollen, E.L.

AU - Blauw, G.J.

AU - Jukema, J.W.

AU - Westendorp, R.G.

PY - 2009

Y1 - 2009

N2 - Observational studies have given conflicting results about the effect of statins in preventing dementia and cognitive decline. Moreover, observational studies are subject to prescription bias, making it hard to draw definite conclusions from them. Randomized controlled trials are therefore the preferred study design to investigate the association between statins and cognition. Here we present detailed cognitive outcomes from the randomized placebo-controlled PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Cognitive function was assessed repeatedly in all 5,804 PROSPER participants at six different time points during the study using four neuropsychological performance tests. After a mean follow-up period of 42 months, no difference in cognitive decline at any of the cognitive domains was found in subjects treated with pravastatin compared to placebo (all p > 0.05). Pravastatin treatment in old age did not affect cognitive decline during a 3 year follow-up period. Employing statin therapy in the elderly in an attempt to prevent cognitive decline therefore seems to be futile. © 2009 Springer-Verlag.

AB - Observational studies have given conflicting results about the effect of statins in preventing dementia and cognitive decline. Moreover, observational studies are subject to prescription bias, making it hard to draw definite conclusions from them. Randomized controlled trials are therefore the preferred study design to investigate the association between statins and cognition. Here we present detailed cognitive outcomes from the randomized placebo-controlled PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Cognitive function was assessed repeatedly in all 5,804 PROSPER participants at six different time points during the study using four neuropsychological performance tests. After a mean follow-up period of 42 months, no difference in cognitive decline at any of the cognitive domains was found in subjects treated with pravastatin compared to placebo (all p > 0.05). Pravastatin treatment in old age did not affect cognitive decline during a 3 year follow-up period. Employing statin therapy in the elderly in an attempt to prevent cognitive decline therefore seems to be futile. © 2009 Springer-Verlag.

U2 - 10.1007/s00415-009-5271-7

DO - 10.1007/s00415-009-5271-7

M3 - Article

VL - 257

SP - 85

EP - 90

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 1

ER -